Newborn Screening Market by Product (Consumables, Instruments) Technology (Tandem Mass Spectrometry, Pulse Oximeter, Molecular Assays, Immune Assays) Application (CHD, Infectious Diseases, Inherited & Hearing Disorders) End User – Global Forecast to 2030

Newborn Screening Market by Product (Consumables, Instruments) Technology (Tandem Mass Spectrometry, Pulse Oximeter, Molecular Assays, Immune Assays) Application (CHD, Infectious Diseases, Inherited & Hearing Disorders) End User – Global Forecast to 2030

The global newborn screening market is projected to reach $2.49 billion by 2030, at a CAGR of 7.9% from 2023 to 2030.

Following a comprehensive primary and secondary study and an in-depth analysis of the market scenario, this report provides the key drivers, constraints, challenges, and opportunities of the industry. This market is driven by the rising prevalence of congenital heart diseases and genetic disorders, the increasing neonatal population, and the rising awareness regarding newborn screening.

Furthermore, emerging economies and government programs & legislation promoting newborn screening provide a significant growth opportunity for this market. However, the shortage of healthcare professionals and the emergence of non-invasive prenatal screening technologies may restrain the growth of this market. Additionally, ethical concerns related to newborn screening and the high costs of genomic newborn testing pose a major challenge for the players operating in this market.

Among products, in 2023, the consumables segment is expected to account for the largest share of the newborn screening market. The large market share of this segment is attributed to the increased demand for consumables for newborn screening, repeat purchases of consumables for newborn screening and the availability of advanced kits.

Among technologies, in 2023, the tandem mass spectrometry segment is expected to account for the largest share of the newborn screening market. The increasing prevalence of genetic disorders, cost-effectiveness, high applicability, short turnaround time, ability to screen multiple diseases simultaneously, and technological advancements are expected to boost the growth of this segment.

Among applications, in 2023, the inherited disorders segment is expected to account for the largest share of the newborn screening market. The large market share of this segment is attributed to factors such as the high prevalence of inherited disorders among newborns, variations and mutations in the genes, inherited gene defects, and abnormality in genetic composition.

Among end users, in 2023, the hospitals segment is expected to account for the largest share of the newborn screening market. The large market share of this segment is attributed to factors such as the high preference for hospitals as childbirth facilities, the growing newborn population, continuous improvements in healthcare infrastructure, utilization of advanced techniques, and the availability of skilled professionals.

An in-depth analysis of the geographical scenario of the global newborn screening market provides detailed qualitative and quantitative insights for the five major geographies (North America, Europe, Asia-Pacific, the Middle East & Africa, and Latin America) along with the coverage of major countries in each region.

In 2023, North America is expected to account for the largest share of the global newborn screening market, followed by Europe, Asia-Pacific, Latin America, and the Middle East & Africa. Asia-Pacific is expected to be the fastest-growing region of the global newborn screening market.

The key players operating in the global newborn screening market are Thermo Fisher Scientific, Inc. (U.S.), ARCHIMED Group (France), PerkinElmer, Inc. (U.S.), Medtronic plc (Ireland), Trivitron Healthcare Pvt Ltd. (India), Bio-Rad Laboratories, Inc. (U.S.), Demant A/S (Denmark), Baebies, Inc. (U.S.), ZenTech s.a. (Belgium), and F. Hoffmann-La Roche AG (Switzerland).

Scope of the Report:

Newborn Screening Market Assessment–by Product

Instruments
Consumables
Newborn Screening Market Assessment–by Technology
Immune Assays & Enzymatic Assays
Tandem Mass Spectrometry
Molecular Assays
Hearing Screening Technologies
Pulse Oximetry
Other Technologies

Note: Other technologies include gel electrophoresis, hematology, microbiology, and urinalysis.

Newborn Screening Market Assessment–by Application

Congenital Heart Disease
Inherited Disorders
Metabolic Disorders
Endocrine Disorders
Hemoglobin Disorders
Other Inherited Disorders
Infectious diseases
Hearing Disorders
Other Applications

Note: Other inherited disorders include galactosemia, biotinidase deficiency, cystic fibrosis, severe combined immunodeficiency (SCID), Pompe disease (glycogen storage disease type II), mucopolysaccharidosis type 1, X-linked adrenoleukodystrophy, and spinal muscle atrophy (SMA).

Note: Other applications include birth injuries, birth trauma, and malformation.

Newborn Screening Market Assessment–by End User

Hospitals
Reference Laboratories

Newborn Screening Market Assessment–by Geography

North America
U.S.
Canada
Europe
Germany
U.K.
France
Italy
Spain
Rest of Europe (RoE)
Asia-Pacific (APAC)
China
Japan
India
Rest of APAC (RoAPAC)
Latin America
Brazil
Mexico
Rest of Latin America (RoLATM)
Middle East & Africa

Newborn Screening Market - Report Summary

Report Metrics	Details
Years Considered	2021 - 2030
Base Year	2023
Forecast Period	2023-2030
Page Count	226
Units Referenced	Value (USD Million)
Segments/Key Topics	Market by Product, Technology, Application, End User, and Geography
Regions Covered	North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa
Key Companies Mentioned	Thermo Fisher Scientific, Inc. (U.S.), ARCHIMED Group (France), PerkinElmer, Inc. (U.S.), Medtronic plc (Ireland), Trivitron Healthcare Pvt Ltd. (India), Bio-Rad Laboratories, Inc. (U.S.), Demant A/S (Denmark), Baebies, Inc. (U.S.), ZenTech s.a. (Belgium), and F. Hoffmann-La Roche AG (Switzerland).

FAQs About the Report

What is the scope of the newborn screening market study?

This market study covers the market sizes & forecasts of the newborn screening market based on product, technology, application, end user, and geography. This market study also provides the value analysis of various segments and subsegments of the newborn screening market at the regional and country levels.

What is the revenue generated from the sale of newborn screening products across the globe? At what rate is their demand expected to grow for the next 5–7 years?

The newborn screening market is projected to reach $2.49 billion by 2030, at a CAGR of 7.9% during the forecast period of 2023–2030.

What are the various products of newborn screening, and which product segment holds the major share of the market?

Based on product, the newborn screening market is segmented into instruments and consumables. In 2023, the consumables segment is expected to account for the largest share of the newborn screening market due to the recurring purchases of consumables for screening of newborns, availability of advanced kits, and high awareness about newborn screening in developed countries.

What are the various technologies of newborn screening, and which technology segment holds the major share of the market?

Based on technology, the newborn screening market is segmented into immune assays & enzymatic assays, tandem mass spectrometry, molecular assays, hearing screening technologies, pulse oximetry, and other technologies. In 2023, the tandem mass spectrometry segment is expected to account for the largest share of the newborn screening market due to its capability to screen multiple diseases or conditions simultaneously, cost-effectiveness, high throughput capability, and rapid turnaround time.

What are the various applications involved in newborn screening, and which application segment holds the major share of the market?

Based on application, the newborn screening market is segmented into congenital heart disease, inherited disorders, infectious diseases, hearing disorders, and other applications and targeted sequencing, whole genome sequencing, whole exome sequencing, and other sequencing types. In 2023, the inherited disorders segment is expected to account for the largest share of the newborn screening market due to the high prevalence of inherited disorders among newborns, variations or mutations in the genes, inherited gene defects, and abnormality in genetic composition.

What are the various end users in the newborn screening market, and which end user segment holds the major share of the market?

Based on end user, the newborn screening market is segmented into hospitals and reference laboratories. In 2023, the hospitals segment is expected to account for the largest share of the newborn screening market due to the high preference of hospitals for childbirth delivery, better infrastructure, utilization of advanced techniques in hospitals, and the availability of skilled professionals.

What are the key factors supporting the growth of this market? What are the major opportunities for the market players in the newborn screening market?

The growth of this market is driven by the rising prevalence of congenital heart diseases and genetic disorders, the increasing neonatal population, and the rising awareness regarding newborn screening. Furthermore, the government programs & legislation promoting newborn screening are expected to provide significant growth opportunities for the players operating in this market.

What are the factors hindering the growth of the newborn screening market?

The shortage of healthcare professionals and the emergence of non-invasive prenatal screening technologies are expected to hinder the growth of this market to a certain extent. In addition, factors such as ethical concerns related to newborn screening and the high costs of genomic newborn testing are the major challenges to the growth of this market.

Who are the major players operating in the newborn screening market?

The key players operating in the newborn screening market are Thermo Fisher Scientific, Inc. (U.S.), ARCHIMED Group (France), PerkinElmer, Inc. (U.S.), Medtronic plc (Ireland), Trivitron Healthcare Pvt Ltd. (India), Bio-Rad Laboratories, Inc. (U.S.), Demant A/S (Denmark), Baebies, Inc. (U.S.), ZenTech s.a. (Belgium), and F. Hoffmann-La Roche AG (Switzerland).

Which regions/countries are expected to offer significant growth opportunities for the vendors operating in the newborn screening market?

The Asia-Pacific region is slated to witness the fastest growth rate during the forecast period and subsequently offer significant growth opportunities for the players operating in this market. The high market growth in Asia-Pacific is driven by governments’ increasing focus on newborn screening, the increasing disposable incomes in Asia-Pacific countries, high fertility rates, and the improving healthcare infrastructure.